title: [Alterations within white blood cell subsets in children with chronic viral hepatitis C before treatment with pegylated interferon and ribavirin].
abstract: OBJECTIVE
  Detection of differences in white blood cell subsets I children with chronic viral hepatitis type C before antiviral treatment.
  
  
  METHODS
  A cohort of children (n = 52) with proven HCV infection were subjected to flow cytometric analysis of their white blood cells and compared to non-infected control group.
  
  
  METHODS
  It has been found that the hepatitis group has higher number of cells with cytotoxic potential, decreased CD4/CD8 ratio than the other one.
  
  
  RESULTS
  Significant rise of CD8+, CD28- cells, NK cells and NKT lymphocytes was demonstrated in hepatitis group. Several correlations were noticed between various cell subsets studied in virus C infected children.
  
  
  CONCLUSIONS
  This data show that HCV infection affects child immunity at systemic level. Cellular alterations are detectable by means of flow cytometry. Evaluation of its parameters might have predictive value in antiviral treatment.
authors.affiliation: Klinika Chorób Zakaźnych i Neurologii Dzieciecej III Katedry Pediatrii, Akademia Medyczna im. Karola Marcinkowskiego w Poznaniu.
authors.forename: Iwona
authors.initials: I
authors.lastname: Mozer-Lisewska
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Dworacki
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Kaczmarek
authors.forename: Wojciech
authors.initials: W
authors.lastname: Słuzewski
authors.forename: Arleta
authors.initials: A
authors.lastname: Kowala-Piaskowska
authors.forename: Magdalena
authors.initials: M
authors.lastname: Figlerowicz
authors.forename: Mariusz
authors.initials: M
authors.lastname: Kaczmarek
authors.forename: Jan
authors.initials: J
authors.lastname: Zeromski
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001402:B-Lymphocytes / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D002648:Child; D002669:Child Welfare; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism; D016131:Lymphocyte Subsets / Q000187:drug effects; D008297:Male; D009000:Monocytes / Q000187:drug effects; D011044:Poland; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b